Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis, Rituxan Hycela, Haegarda

Executive Summary

Original new drugs and biologics recently approved by US FDA.

You may also be interested in...



Halozyme Lands Largest Enhanze Deal To Date With Bristol

Bristol will pay $105m up front and as much as $1.76bn in milestone fees to use the Enhanze technology in drugs against up to 11 immuno-oncology targets. Also, Roche will pay up to $190m to add a target to an existing partnership.

Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership

Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.

Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus

The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might want to exit the primary care ADHD space.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel